DCGI gives nod to Cadila Healthcare to conduct phase-III trials for two-dose COVID vaccine

Cadila Healthcare yesterday said it has received permission from the Indian drug regulator for conducting phase IIItrials for its two-dose COVID-19 vaccine ZyCoV-D.

The company has already received the Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on 20th August.

The company has “… got the permission for conduct of phase-III trials for two-dose COVID vaccine,” Cadila Healthcare said in a regulatory filing.

Earlier in August, in a filing to BSE, the company had said that it plans to seek approval for the two-dose regimen of the vaccine. It had also mentioned that the company plans to manufacture 10-12 crore doses of ZyCoV-D annually.